Project Grant R21AI193963
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $451,956 Project Grant on August 15, 2025 to Baylor College of Medicine under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the mechanisms by which the syphilis-causing bacterium Treponema pallidum invades and impacts the placenta. The project aims to use novel in vitro models of trophoblast cells and organoids to characterize T. pallidum attachment, growth, and internalization, as well as...
- This $698,349 Project Grant awarded on February 25, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of an "Integrated Multiplexed Diagnostic Assay Targeting Fusion Lipoproteins and Cardiolipin for Detection of Treponemal and Nontreponemal Antibodies in Syphilis Patients." The goal is to create a rapid, point-of-care diagnostic test that can definitively diagnose...
- The University of Washington was awarded a $485,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, awarded on August 11, 2025, will fund research to elucidate the role of genetic recombination in Treponema pallidum, the bacterium that causes syphilis. Specifically, the researchers will investigate the mechanisms of homologous recombination in T. pallidum and examine...
- This Project Grant award of $448,150 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to explore how the syphilis-causing bacterium Treponema pallidum avoids complement-mediated killing by recruiting the human complement inhibitor Factor H. The goal is to improve understanding of syphilis pathogenesis and identify new control strategies, as syphilis remains a public health concern...
- This federal Project Grant award of $283,694 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research by Dalhousie University to investigate how the syphilis bacterium, Treponema pallidum, interacts with the cervicovaginal epithelial barrier and whether the vaginal microbiome influences susceptibility to T. pallidum infection. The research aims to advance the understanding of syphilis transmission dynamics and...
- The University of Connecticut Health Center (UCHC) was awarded a $457,875 Project Grant by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate fundamental aspects of syphilis disease pathogenesis, including nutrient acquisition and environmental sensing by the bacteria Treponema pallidum. The grant, which spans from August 1, 2025 to July 31, 2027, will support research activities to...
- This federal Project Grant award of $445,250.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to establish a mouse model of congenital syphilis (CS) and determine changes in the host immune response. The primary goals are to lay the foundation for developing improved diagnostics and vaccines for syphilis, a sexually transmitted disease with increasing global incidence. The grant, awarded to...
- This federal Project Grant award of $426,625.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to assess the feasibility of using the Dual Path Platform (DPP) Syphilis TNT assay for the longitudinal evaluation of syphilis treatment response and reinfection. The project, titled "Quantitative Assessment of the DPP Syphilis TNT Assay in Infection and Treatment Response", will be...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $165,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Tufts University School of Medicine for the development of an improved transposon mutagenesis system to enable comprehensive genetic analysis of Borrelia burgdorferi, the bacterium that causes Lyme disease. The project aims to create a high-efficiency transposon insertional mutagenesis system for B. burgdorferi to...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $243,235 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. This grant will fund the development and validation of direct-from-sample whole genome sequencing methods for Neisseria gonorrhoeae (NG) to support expanded genomic surveillance of NG and other bacterial sexually transmitted infections in populations with high HIV burdens in Eastern and...
This Project Grant award of $418,360.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Program (CFDA 93.855), aims to systematically analyze Treponema pallidum gene expression under host infection-related conditions. The central hypothesis is that T. pallidum, the bacterium that causes syphilis, alters its gene expression in response to changes in oxygen concentration, temperature, and host interactions, which enables its ability to colonize and disseminate within and between hosts. The proposed research will investigate the impact of these environmental factors on T. pallidum gene expression using RNA-seq and reverse transcription droplet digital PCR. It will also determine the abundance of T. pallidum in various host tissues during rabbit infections and examine how its gene expression changes during colonization of different tissues. This research is expected to provide new insights into the biology and pathogenesis of syphilis, informing efforts to develop improved treatments and preventative measures.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $418.4k | 8/11/25 |